Print this page
-
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Biomarkers of Oral Carcinogenesis and Oral Cancer Pain
Protocol: 032202Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer.
Protocol: 032309Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Preoperative Plasma ctDNA Detection in Early Stage Cancer: A Proof-of-Concept Evaluation
Protocol: 032308Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Colon
Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer.
Protocol: 032309Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Protocol: 032409Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/ Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Protocol: 032409Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial.
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/ Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial.
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung